TITLE

BIOMS REPORTS ON PHASE II DIRUCOTIDE FOR MULTIPLE SCLEROSIS

PUB. DATE
March 2009
SOURCE
Worldwide Biotech;Mar2009, Vol. 21 Issue 3, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports on the results from MINDSET-01, an exploratory phase II clinical trial evaluating dirucotide in patients with relapsing-remitting multiple sclerosis (MS), released by BioMS Medical Corp. The results of the study showed that dirucotide did not meet its primary endpoint, annualized relapse rate or associated secondary magnetic resonance imaging (MRI) endpoints. The study also revealed that the drug did meet certain secondary endpoints related to the progression of the disease.
ACCESSION #
36633492

 

Related Articles

  • Controversies in Multiple Sclerosis Therapy. Rizzo, Toni // MD Conference Express;Jun2014, Vol. 14 Issue 6, p18 

    Considerable progress has been made in multiple sclerosis (MS) therapy in the 20 years since the first successful trial. Although several agents are now available for treating patients with MS, many issues remain regarding treatment of individual patients. This article discusses initiating MS...

  • Merck reports encouraging data from Phase III multiple sclerosis trial.  // PharmaWatch: CNS;Aug2009, Vol. 8 Issue 8, p8 

    The article reports on the new data unveiled by Merck Serono SA from a two-year placebo-controlled Clarity Phase III trial which examined the efficacy of cladribine tablets in treating patients with relapsing-remitting multiple sclerosis. According to the data, the cladribine tablets can improve...

  • Overview of London trial of intramuscular interferon-�1a in primary-progressive multiple sclerosis. Miller, David H.; Leary, Siobhan M.; Thompson, Alan J. // Multiple Sclerosis (13524585);Jun2004 Supplement, Vol. 10, p56 

    This short monograph describes the rationale, design and outcome of a pilot study of beta interferon in patients with primary progressive MS. A total of 50 patients were studied for 2 years using a randomized, double-blinded, placebo-controlled design. There was an emphasis on using MRI measures...

  • Glatiramer effective in delaying clinical MS.  // Formulary;Jun2008, Vol. 43 Issue 6, p220 

    The article reports on the findings of the study called PRECISE, a randomized trial of patients presented with a single clinical episode and a magnetic resonance imaging (MRI) scan suggestive of multiple sclerosis (MS). This study found that glatiramer provides a new option for delaying...

  • Methodology of clinical trials in multiple sclerosis. Mitsikostas, D. D. // Neurological Sciences;Sep2006 Supplement 5, Vol. 27, ps362 

    The scope of the paper is to summarise key issues in methodology used in clinical trials on multiple sclerosis (MS) treatment and help clinicians to better understand articles reporting the results of these trials. Relapsing ratio and disability progression based on the Expanded Disability...

  • Does MRI lesion activity regress in secondary progressive multiple sclerosis? Zhao, Y.; Petkau, A. J.; Traboulsee, A.; Riddehough, A.; Li, D. K. B. // Multiple Sclerosis (13524585);Apr2010, Vol. 16 Issue 4, p434 

    Background: The rate of new contrast-enhancing lesions (CELs) on monthly magnetic resonance imaging (MRI) scans has been shown to decrease over a 9-month period in placebo-treated patients with relapsing-remitting (RR) multiple sclerosis (RRMS). Objective: We examined this phenomenon in...

  • Multiple Sclerosis Update.  // PharmaWatch: CNS;Apr2008, Vol. 7 Issue 4, p7 

    The article offers news briefs related to results of clinical trials for treatment of multiple sclerosis. BioMS Medical Corp. has revealed that the Data Safety Monitoring Board (DSMB) has recommended to the company to continue the trial for its MBP8298 drug. Likewise, Opexa Therapeutics Inc. has...

  • Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs. Sormani, M. P.; Bonzano, L.; Roccatagliata, L.; De Stefano, N. // Multiple Sclerosis Journal;May2011, Vol. 17 Issue 5, p630 

    Recent studies have provided evidence for using magnetic resonance imaging (MRI) active lesions as surrogate for relapses and disability progression in multiple sclerosis (MS). However, the validity of MRI metrics as surrogate endpoints in MS is controversial. Furthermore, the extrapolation of...

  • Further investigation of safety monitoring guidelines based on magnetic resonance imaging lesion activity in multiple sclerosis clinical trials. Dong, Jing; Zhao, Yinshan; Petkau, A John; Li, David KB; Riddehough, Andrew; Traboulsee, Anthony // Multiple Sclerosis Journal;Jan2015, Vol. 21 Issue 1, p101 

    We assess two modified guidelines for monitoring patient safety in multiple sclerosis (MS) trials. These guidelines flag patients with an increase in contrast enhancing lesion (CEL) count above a threshold over the CEL level 1–2 months earlier. We compare the new guidelines to the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics